Page 6 - சூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

HKUMed discovers a novel mediator of liver fibrosis and its underlying mechanism that can be a new therapeutic target

Date Time Share HKUMed discovers a novel mediator of liver fibrosis and its underlying mechanism that can be a new therapeutic target HKUMed discovers a novel mediator of liver fibrosis and its underlying mechanism that can be a new therapeutic target. The research was led by Dr Ruby Hoo Lai-chong (second from left), Assistant Professor, Department of Pharmacology and Pharmacy, HKUMed and Co-investigator of State Key Laboratory of Pharmaceutical Biotechnology, HKU. Dr Wu Xiaoping (second from right), post-doctoral fellow, Department of Pharmacology and Pharmacy, HKUMed is the first author. Other research team members include: Ms Zong Jiuyu (left) and Ms Zhang Zixuan (right), postgraduate student, Department of Pharmacology and Pharmacy, HKUMed.

United statesHong kongLi jingjingZong jiuyuZhang zixuanWang cunchuanRuby hoo lai chongShu linglingWu xiaopingHealth bureauKey laboratory of pharmaceutical biotechnologyUniversity of hong kong hkumedResearch grants councilDepartment of medicineTechnology programCollaborative research fund

Sound Biologics Announces Proof-of-Concept Success at AACR Annual Meeting

Share this article Share this article BOTHELL, Wash., April 13, 2021 /PRNewswire/ Qilu Puget Sound Biotherapeutic Corp. (Sound Biologics), an emerging biotechnology company focused on developing a novel MabPair ™ platform for antibody-based combination therapies for the treatment of cancer, inflammation and autoimmune disease, announced a clinical update on its first MabPair product PSB205 at the American Association for Cancer Research (AACR) Annual Meeting. Dr Li Zhang of Sun Yat-Sen University Cancer Centre (SYSUCC), Guangzhou, China presented a poster on Phase 1 Clinical Trial results of PSB205, a combination of anti-PD1 and anti-CTLA-4 antibodies that are manufactured together as a single product, in patients with advanced malignant tumors. The study is sponsored by Qilu Pharma in China.

Li zhangUnited statesQilu pharmaWei yanJelle kijlstraAmerican association for cancer researchSun yat sen university cancer centreQilu puget sound biotherapeutic corpPrnewswire qilu puget sound biotherapeutic corpSound biologicsAmerican associationCancer researchPreliminary clinical activityManufactured togetherPhasei clinicalE poster session

Kintara Presents Updates on Two Phase 2 Clinical Trials at the 2021 American Association for Cancer Research Annual Meeting

Kintara Presents Updates on Two Phase 2 Clinical Trials at the 2021 American Association for Cancer Research Annual Meeting News provided by Share this article Share this article SAN DIEGO, April 12, 2021 /PRNewswire/ Kintara Therapeutics, Inc. (Nasdaq: KTRA) ( Kintara or the Company ), a biopharmaceutical company developing novel cancer therapies for patients who are failing, or resistant to, current treatment regimens, today announced interim data results from two Phase 2 clinical trials evaluating VAL-083, the Company s lead compound, for the treatment of glioblastoma multiforme (GBM). The data were presented in two posters at the 2021 American Association for Cancer Research (AACR) Annual Meeting, which is taking place virtually from April 10-15, 2021.

United statesSan diegoN eng jmedJules abrahamNational cancer instituteGlobal coalition for adaptive researchCompany current reports on formKintara therapeutics incMd anderson cancer centerCompany quarterly reports on formSun yat sen university cancer centerCompany annual report on formAmerican association for cancer researchKintara therapeuticsCancer researchAnnual meeting

Kintara Therapeutics Inc says interim Phase 2 study data on VAL-083 shows its potential as game-changing treatment option for GBM patients

Kintara Therapeutics Inc says interim Phase 2 study data on VAL-083 shows its potential as game-changing treatment option for GBM patients
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

United statesAmerican association for cancer researchGlobal coalition for adaptive researchMd anderson cancer centerSun yat sen university cancer centerCancer researchCancer centerGlobal coalitionAdaptive researchDiego based kintaraஒன்றுபட்டது மாநிலங்களில்அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சிஉலகளாவிய கூட்டணி க்கு மாற்றி அமைக்கத்தக்க ஆராய்ச்சிம்ட் ஆண்டர்சன் புற்றுநோய் மையம்சூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய் மையம்புற்றுநோய் ஆராய்ச்சி

NA Proactive news snapshot: Fury Gold Mines Limited, INDVR Brands Inc, Aurania Resources Ltd, Alternus Energy Group PLC …

NA Proactive news snapshot: Fury Gold Mines Limited, INDVR Brands Inc, Aurania Resources Ltd, Alternus Energy Group PLC …
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUnited kingdomUniversity of colorado denverCliff creekJoshua mannGraham simmondsFarmako gmbHania szajewskaStadapharm gmbRoland boivinVincent browneCharles beaudryCarina venterP peter pascaliJason dyck